Navigation Links
Dong-A PharmTech Co., Ltd. Announces Positive Results for Udenafil,,Its New Long Acting Drug For Erectile Dysfunction

icantly (p<0.001) higher compared to 31% in the placebo group. Fifty percent (50%) of the patients in the 150mg group shifted to normal erectile function (EF domain scores >25) after 12 weeks on drug compared to 14% in the placebo group. All three active dose levels were well-tolerated; the most frequently reported adverse events were nasal congestion, flushing and headache and were mostly mild to moderate in intensity. No myalgia, back pain, leg pain or vision disturbances were reported and no serious adverse events related to the drug were reported. Only 4 patients withdrew from the study due to adverse events related to the drug.

Dong-A PharmTech Co., Ltd anticipates that the completion of the phase 2b trial will allow it to proceed with phase 3 clinical trials in the U.S. and Europe.

"We are extremely pleased with the results of this 340 patient phase 2b clinical trial in the U.S. which clearly demonstrated an excellent efficacy and safety profile in erectile dysfunction patients," stated Dong Hyun Park, President and CEO of Dong-A PharmTech. "The completion of this study is a major milestone in the development of udenafil. We plan to aggressively pursue regulatory approval in major markets throughout the world and to replicate in those markets the commercial success already achieved in Korea."

Udenafil was approved by the Korean FDA in November 2005 and launched by Dong-A Pharmaceutical in Korea under the brand name Zydena(R) in late December 2005 as the fourth entrant to the ED market. By the first quarter of 2006, Zydena(R) garnered 21% market share in Korea in terms of tablet volume and effectively expanded the Korean ED market volume by 16% through the introduction of new patients as well as re-entry of former patients. To date, Zydena(R) has maintained its market share, surpassing Levitra(R), and nearly reaching parity with Cialis(R) by sales volume.

Dong-A PharmTech Co., Ltd. has initiated the approval process for udenafil in C
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:8/27/2014)... -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a global ... participating in the Morgan Stanley 2014 Global Healthcare Conference ... New York , on Tuesday, September 9, 2014.  ... will be presenting at 9:10 a.m. Eastern Time.  ... join Mr. Dvorak for the Q&A session. ...
(Date:8/27/2014)... -- Sinovac Biotech Ltd. (NASDAQ: SVA ), a leading ... announced the results of the Company,s 2014 Annual General Meeting of ... , PRC. The required quorum, a majority of the common ... shareholders approved the following proposals:  , The re-election of ... Anderson , Kenneth Lee and Meng Mei ...
(Date:8/27/2014)...  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ... commercialization of innovative therapies for the treatment of acute ... be participating at the FBR Healthcare One on One ... Conference.  Details of the two events are as follows: ... Wednesday September 3 rd Location: Four Seasons, ...
Breaking Medicine Technology:Sinovac Announces Results of 2014 Annual General Meeting of Shareholders 2AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 2AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 3
... April 18, 2011 Qmed.com, a UBM Canon ... informative video clips of products and services available ... Vault . Qmed is a free online search ... access to pre-qualified medical device suppliers. ...
... 18, 2011 Nektar Therapeutics (Nasdaq: NKTR ) ... March 31, 2011 on Wednesday, April 27, 2011, after the ... executive officer, will host a conference call to review the ... Time (PT). The press release and a ...
Cached Medicine Technology:Qmed Video Vault Showcases Innovative New Products and Services Available to Medical Device Manufacturers 2Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets 2
(Date:8/27/2014)... August 27, 2014 IQ Formulations ... today announced its continued support of the Cystic Fibrosis ... participated in a fundraising campaign led by TigerFitness.com in ... IQ Formulations’ sales were donated to the respected nonprofit ... a TigerFitness.com fundraiser to support Isla, a young girl ...
(Date:8/27/2014)... Aspirus Wausau Hospital today announced the first extensive ... O.R. at Aspirus Wausau Hospital, in Wausau, WI. ... will be Buzz, a centralized surgical hub for operating ... navigation, imaging and communications connectivity. , Buzz Digital ... hardware all controlled from the full HD 42” multi-touch ...
(Date:8/27/2014)... 27, 2014 SCOTT Sports is ... Utah’s first indoor mountain bike and BMX park. SCOTT ... bikes in both adult and youth sizes for the park’s ... a distribution warehouse in Ogden, Utah, recently moved its U.S. ... “We are proud to be a partner with the Wasatch ...
(Date:8/27/2014)... By Steven Reinberg ... -- A hormone used to reduce the need for blood ... new study suggests. Synthetic erythropoietin (EPO), which stimulates red ... shortly after preterm birth, said lead researcher Dr. Petra Huppi, ... of Geneva, in Switzerland. "The real test of whether ...
(Date:8/27/2014)... CIC microGUNE, the Co-operative Research Centre into ... seeks to generate innovative solutions based on ... mobility industry and life sciences, among others. ... Tecnun are collaborating with CIC microGUNE on ... funded by the Etortek 2013-2014 programme of ...
Breaking Medicine News(10 mins):Health News:IQ Formulations Contributes Sizeable Donation to Cystic Fibrosis Foundation 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 3Health News:SCOTT Sports to Sponsor Wasatch Indoor Bike Park 2Health News:Hormone Might Help Preemies' Brains 2Health News:Hormone Might Help Preemies' Brains 3Health News:Microtechnologies for driving forward mobility and human health 2
... hearing damage from acoustic shock, say health experts. // , ... functioning of the ear or of the nervous system, which ... earphone by a sudden sharp rise in the acoustic pressure ... a bleep or any unexpected noise. Two thirds of call ...
... For patients on hemodialysis, the use of dialysis filters ... approach to the common problem of anemia, reports a ... 39th Annual Meeting and Scientific Exposition in San Diego. ... Hospital in Vicenza, Italy, analyzed the outcomes of 172 ...
... acquired respiratory syndrome (SARS), has been responsible for around ... Researchers from Brookhaven’s biology department and the National Synchrotron ... controlling the virus . They have successfully identified a ... new anti-SARS virus drugs.The stage has been set now ...
... bypass surgery for morbid obesity have increased risk factors ... paper being presented at the American Society of Nephrology's ... ,'Gastric bypass surgery appears to lead to changes ... the formation of kidney stones,' comments Dr. Rajiv Kumar ...
... of clear information about the risks of nanotechnology in ... this powerful potential according //to 14 top international scientists ... issue of the journal Nature. The paper, 'Safe Handling ... nanotechnology risk that must be met if the technology ...
... China for stem cell treatment died on Thursday night in ... ,Willie Terpstra, a New Zealander, was diagnosed with motor ... months ago to have a foetal cell tansplantation operation in ... of voluntary muscle activity that aids speaking, breathing and swallowing. ...
Cached Medicine News:Health News:Vitamin E-Coated Dialysis Filters Help Fight Anemia in Hemodialysis Patients 2Health News:Scientists Close To Identifying Anti-viral Drug for SARS 2Health News:Scientists Close To Identifying Anti-viral Drug for SARS 3Health News:Gastric Bypass Surgery May Lead to Increased Kidney Stone Risk 2Health News:Fear of Possible Harm Hinder Nanotech Development 2
Inquire...
Inquire...
Protects the skin over extended wearing time from irritating discharge. Flextend skin barrier is the barrier of choice for urostomies and ileostomies with the added benefit of it being discreet in bo...
Inquire...
Medicine Products: